Ra Pharmaceuticals, Inc.
Industry
- Biotechnology
- Large Molecule
- Drug Discovery Technologies
- Antisense, Oligonucleotides
- Pharmaceuticals
Other Names/Subsidiaries
- UCB S.A.
Latest on Ra Pharmaceuticals, Inc.
UCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d
Mariana Oncology Inc. CEO Simon Read believes that one of the reasons his company was able to raise the $175m series B venture capital round announced on 7 September was its differentiated approach t
UCB S.A. ’s complement component 5 (C5) inhibitor peptide zilucoplan hit the primary endpoint and two secondary endpoints in a Phase III study in generalized myasthenia gravis (gMG), the firm announce
UCB S.A. has moved closer to becoming a major player in the generalized myasthenia gravis (gMG) space with rozanolixizumab, one of the Belgian group's two late-stage candidates for the rare autoimmun